Cumberland Pharmaceuticals Inc. (CPIX) earnings
CPIX earnings moved a median of -4.03% by the close. Quarterly and annual CPIX reports and results, each read against the price at its own news timestamp. Back to the CPIX overview →
22 measured CPIX earnings events.
Where these CPIX earnings landedvs 21 measured CPIX earnings reactions
| Middle 50% of CPIX earnings reactions | -7.65% to +0.66% |
|---|---|
| Median reaction (to close) | -4.03% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 CPIX earnings events with a measured close landed between -7.65% and +0.66%; 29% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Jun 30 | SEC filing · Form 10-Q | -0.26% | — | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.66% | |
| Form 10-K CUMBERLAND PHARMACEUTICA For: Dec 31 | SEC filing · Form 10-K | +3.26% | -0.87% | |
| CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH | Press release | -0.66% | -19.87% | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Sep 30 | SEC filing · Form 10-Q | +0.96% | -5.26% | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Jun 30 | SEC filing · Form 10-Q | -2.25% | -8.68% | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Mar 31 | SEC filing · Form 10-Q | +8.02% | +9.79% | |
| Form 10-K CUMBERLAND PHARMACEUTICA For: Dec 31 | SEC filing · Form 10-K | -3.44% | -21.91% | |
| Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth | Press release | -0.17% | +17.74% | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Sep 30 | SEC filing · Form 10-Q | -3.23% | -3.23% | |
| Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update | Press release | +0.52% | +2.59% | |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS | Press release | — | +0.90% | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Jun 30 | SEC filing · Form 10-Q | -0.70% | -0.70% | |
| Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 | Press release | -0.66% | -1.33% | |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS | Press release | — | -4.03% | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Mar 31 | SEC filing · Form 10-Q | — | -5.36% | |
| Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update | Press release | +5.58% | +1.83% | |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS | Press release | +0.00% | -4.70% | |
| Form 10-K CUMBERLAND PHARMACEUTICA For: Dec 31 | SEC filing · Form 10-K | — | -4.23% | |
| Form 10-Q CUMBERLAND PHARMACEUTICA For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -8.00% | |
| Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results | Press release | -3.06% | -7.65% | |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS | Press release | +0.00% | -7.77% |
Keep exploring
More CPIX: analyst actions → · SEC filings → · CPIX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Intra-Cellular Therapies Inc. (ITCI) | 247 | -0.04% | 44% |
| Avadel Pharmaceuticals plc - Ordinary Share (AVDL) | 246 | -0.16% | 42% |
| electroCore, Inc. (ECOR) | 245 | 0.00% | 47% |
| Oragenics Inc. (OGEN) | 245 | -0.79% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.